PRN: Global Bronchodilators Market to Grow at a CAGR of 4.7% by 2021: Innovative Technologies for Drug Delivery Drive Growth

01/ago/2017 14:15:10 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Bronchodilators Market to Grow at a CAGR of 4.7% by 2021: Innovative Technologies for Drug Delivery Drive Growth


DUBLIN, August 1, 2017 /PRNewswire/ --

The "Global Bronchodilators Market 2017-2021" report has been added to Research and Markets' offering.

Research and Markets Logo

The global bronchodilators market to grow at a CAGR of 4.78% during the period 2017-2021.

The report, Global Bronchodilators Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is the innovative technologies for drug delivery. Technological advances and innovations in the healthcare industry have resulted in the development of drugs and delivery devices as per the end-user requirement. New technologies in the development of drugs, which can be easily administered and exhibit higher efficacy are more preferred in the market. For instance, in April 2016 AstraZeneca received approval from the US FDA for Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol for patients suffering from COPD. The drug is the company's first product to use its patented Co-Suspension Technology.

According to the report, one of the major drivers for this market is the market potential toward mAb. Monoclonal antibodies are expected to boost the market growth for the treatment of asthma, owing to the development of target specific drugs. mAb blocking immunoglobulin E (IgE) are specifically approved for the treatment of allergic asthma. Also, the mAb against immunoglobulin or specific cytokines, which are known to be important in the initiation or persistence of asthmatic inflammation are being developed.

Further, the report states that one of the major factors hindering the growth of this market is the increased preference for CAM. People who have asthma tend to adopt alternative methods of treatment instead of pharmacologic treatments. According to a recent report, in the US, more than 15% of the population suffer from allergic diseases including allergic asthma, allergic rhinitis, and atopic dermatitis, and more than 40% of people used CAM for these conditions. The usage of CAM for allergic conditions is higher in some European countries, because of efficacy, safety, and low cost of some therapies. The lack of a well-designed clinical trial for these treatments makes it difficult to determine the safety and effectiveness over pharmacotherapies.

Key vendors

  • AstraZeneca
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • GlaxoSmithKline

Other prominent vendors

  • ALK-Abello
  • Amgen
  • Array BioPharma
  • Astellas Pharma
  • Atopix Therapeutics
  • CHIESI Farmaceutici
  • Dynavax Technologies
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Others

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Pipeline analysis

PART 06: Market landscape

PART 07: Market segmentation by drug class

PART 08: Geographical segmentation

PART 09: Decision framework

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Key vendor analysis

PART 14: Appendix

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


blog comments powered by Disqus è un servizio offerto da Factotum Srl